Altimmune, Inc. ALT
2.08 USD +0.11 (+5.58%)
At closeNov 6, 2026, 7:58 PM EST
2.07 -0.01 -0.48%
After hours · Nov 6, 7:58 PM ET
1.95 Day range 2.10
1.97 52-week range 6.18
- YTD
- -42.38%
- 1 year
- -47.21%
News
benzinga.com Altimmune To Present Phase 2 RECLAIM Results For Pemvidutide In Alcohol Use Disorder At AASLD Liver Meeting; FDA End-Of-Phase 2 Meeting Set For December First presentation at a scientific conference of key data from RECLAIM, a multicenter Phase 2 trial of a balanced 1:1 glucagon/GLP-1 receptor agonist in alcohol use disorder (AUD)Presentation to take…
globenewswire.com Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026 MORRISTOWN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 receptor agonist,…
benzinga.com Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $17 Evercore ISI Group analyst Liisa Bayko maintains Altimmune (NASDAQ:ALT) with a Outperform and lowers the price target from $18 to $17.
benzinga.com 9 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Altimmune Q2 EPS $(0.12) Beats $(0.15) Estimate Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 55.56 percent increase over losses of $(0.27) per…
benzinga.com Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study Altimmune reports positive Phase 2 RECLAIM trial data for pemvidutide in AUD and plans to request an EOP2 meeting with the FDA.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $97.4 million. Prelude Therapeutics (NASDAQ:PRLD)…- benzinga.com Altimmune Says Topline Data From RECLAIM Phase 2 Trial Of Pemvidutide For Alcohol Use Disorder Met Its Primary Endpoint Showing Statistically Significant Reduction In Heavy Drinking Days Vs. Placebo Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial Important secondary endpoints were also met,…
- benzinga.com Leerink Partners Initiates Coverage On Altimmune with Outperform Rating, Announces Price Target of $10 Leerink Partners analyst Thomas Smith initiates coverage on Altimmune (NASDAQ:ALT) with a Outperform rating and announces Price Target of $10.
benzinga.com Altimmune Announces New Data From Phase 2b Trial Of Pemvidutide Showing Improvements Across Multiple Non-Invasive Tests Of Metabolic Dysfunction-Associated Steatoheaptitis Activity And Fibrosis. The data are being presented today and Friday in poster sessions, including a late-breaking poster presentation, at the European Association for the Study of the Liver (EASL) Congress 2026 in…- benzinga.com HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $20 HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $25 to $20.
- benzinga.com Citizens Maintains Market Outperform on Altimmune, Lowers Price Target to $11 Citizens analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and lowers the price target from $14 to $11.
benzinga.com Altimmune Q1 2026 Earnings Call: Complete Transcript - benzinga.com Altimmune To Present Analyses Of Data From IMPACT Phase 2b Clinical Trial In Metabolic Dysfunction-Associated Steatohepatitis At EASL Congress 2026 Abstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in "Best of EASL 2026" by EASLOral presentation will highlight further the 48-week IMPACT efficacy and…
benzinga.com Altimmune Q1 EPS $(0.18) Beats $(0.25) Estimate. Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.25) by 28 percent. This is a 30.77 percent increase over losses of $(0.26) per…
benzinga.com Earnings Scheduled For May 13, 2026 - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Why Is Altimmune Stock Falling Today? Altimmune shares fall after a $225 million offering raises dilution concerns while funding key late-stage trials.
benzinga.com ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks declining in pre-market trading. Photo: Shutterstock
benzinga.com ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks declining in pre-market trading. Photo: Shutterstock
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Altimmune Announces Public Offering; Quantity And Termination Date Not Disclosed Altimmune intends to use the net proceeds from this proposed offering to fund its upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH), as well as for working capital and…
benzinga.com HC Wainwright & Co. Maintains Buy on Altimmune, Raises Price Target to $25 HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy and raises the price target from $12 to $25.
benzinga.com B. Riley Securities Maintains Buy on Altimmune, Lowers Price Target to $13 B. Riley Securities analyst William Woods maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $18 to $13.
benzinga.com Altimmune: Q4 Earnings Insights 
benzinga.com Altimmune Q4 EPS $(0.27) Up From $(0.33) YoY, Sales $26.000K Up From $5.000K YoY Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.27) per share. This is a 18.18 percent increase over losses of $(0.33) per share from the same period last year. The company reported $26.000…- benzinga.com Earnings Scheduled For March 5, 2026
benzinga.com What to Expect from Altimmune's Earnings 
benzinga.com Altimmune (ALT) Shares Slide On $75 Million Stock Offering Altimmune shares are tumbling on Wednesday following the company's announcement of a $75 million registered direct offering of common stock.
benzinga.com Qorvo, Altimmune, United Microelectronics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why F5 Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket 
benzinga.com Booz Allen Posts Upbeat Q3 Earnings, Joins Life360, Redwire And Other Big Stocks Moving Higher On Friday 
benzinga.com Why Are Investors Looking At Altimmune Stock? Shares of Altimmune, Inc. (NASDAQ: ALT) are rising Monday after the FDA granted Breakthrough Therapy Designation for Pemvidutide.
benzinga.com Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday - benzinga.com Market-Moving News for January 5th ALT: 24% | Altimmune shares are trading higher after the FDA granted Breakthrough Therapy Designation for Pemvidutide in MASH. RDHL: 52% | RedHill Expands RHB-102 Clinical Development Addressing GLP-1
- benzinga.com Altimmune Says FDA Grants Breakthrough Therapy Designation For Pemvidutide, Balanced 1:1 Glucagon/GLP-1 Dual Receptor Agonist, For Treatment Of Patients With MASH Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today announced the U.S. Food and Drug Administration (FDA) has…
benzinga.com Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks Altimmune reports positive 48-week Phase 2b data for pemvidutide in MASH, showing fibrosis improvement, weight loss, and strong tolerability.- benzinga.com Altimmune's Topline Results From IMPACT Phase 2b Trial Of Pemvidutide For Metabolic Dysfunction-Associated Steatohepatitis Showed Improvement In Antifibrotic Activity With Both Treatment Doses Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepointAdditional weight loss from 24 to 48 weeks with 1.8…
benzinga.com Altimmune Announces Publication In The Lancet Of 24-Week Efficacy And Safety Data From Ongoing IMPACT Phase 2b Trial Of Pemvidutide In Patients With MASH 24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profileSignificant improvements observed in…
benzinga.com Citizens Maintains Market Outperform on Altimmune, Lowers Price Target to $14 Citizens analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and lowers the price target from $15 to $14.- benzinga.com Altimmune Data From AI-Based Analysis Of Biopsies From IMPACT Phase 2b Trial Of Pemvidutide Demonstrates Reductions In Proportionate Areas Of Early, Advanced And Total Liver FibrosisAt 24 Weeks Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced results from an…
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com 10 Health Care Stocks With Whale Alerts In Today's Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
- benzinga.com Earnings Scheduled For August 12, 2025
benzinga.com Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session 
benzinga.com Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket